Identifying the challenges of biomarkers that predict response to HER2-directed therapies.

about

Identifying the challenges of biomarkers that predict response to HER2-directed therapies.

Item

http://www.wikidata.org/entity/Q43628088

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Identifying the challenges of ...... se to HER2-directed therapies.

@en

Identifying the challenges of ...... se to HER2-directed therapies.

@nl

type

Item

label

Identifying the challenges of ...... se to HER2-directed therapies.

@en

Identifying the challenges of ...... se to HER2-directed therapies.

@nl

prefLabel

Identifying the challenges of ...... se to HER2-directed therapies.

@en

Identifying the challenges of ...... se to HER2-directed therapies.

@nl

P1476

Identifying the challenges of ...... se to HER2-directed therapies.

@en

P2093

Neil M Iyengar

http://www.w3.org/2001/XMLSchema#string

Patrick G Morris

http://www.w3.org/2001/XMLSchema#string

P2860

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer

Trastuzumab--mechanism of action and use in clinical practice

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

Recent advances in novel targeted therapies for HER2-positive breast cancer.

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

P304

1437-1440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1517/14656566.2013.803069

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236937115

http://www.w3.org/2001/XMLSchema#string

P698

23705932

http://www.w3.org/2001/XMLSchema#string

P921

biomarker